Literature DB >> 21779211

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.

Michael Gnant1.   

Abstract

Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.

Entities:  

Year:  2010        PMID： 21779211      PMCID： PMC3132953          DOI： 10.1159/000322099

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  27 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.

Authors:  Kyriaki Mystakidou; Emmanuela Katsouda; Efi Parpa; Alexis Kelekis; Antonis Galanos; Lambros Vlahos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Osteoporosis due to cancer treatment: pathogenesis and management.

Authors:  J Pfeilschifter; I J Diel
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

4.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

5.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

Authors:  P D Delmas; R Balena; E Confravreux; C Hardouin; P Hardy; A Bremond
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Bone mineral density changes during the menopause transition in a multiethnic cohort of women.

Authors:  Joel S Finkelstein; Sarah E Brockwell; Vinay Mehta; Gail A Greendale; MaryFran R Sowers; Bruce Ettinger; Joan C Lo; Janet M Johnston; Jane A Cauley; Michelle E Danielson; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

7.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.

Authors:  Dawn L Hershman; Donald J McMahon; Katherine D Crew; Serge Cremers; Dinaz Irani; Gina Cucchiara; Lois Brafman; Elizabeth Shane
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

8.  Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.

Authors:  Tiina Saarto; Leena Vehmanen; Carl Blomqvist; Inkeri Elomaa
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

9.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Authors:  Georgiana K Ellis; Henry G Bone; Rowan Chlebowski; Devchand Paul; Silvana Spadafora; Judy Smith; Michelle Fan; Susie Jun
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544

10.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Authors:  Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis
Journal:  Breast Cancer Res       Date:  2006-03-15       Impact factor: 6.466
View more
  1 in total

1.  Osteooncology - Specific Aspects in Breast Cancer Patients.

Authors:  Raimund Jakesz
Journal:  Breast Care (Basel)       Date:  2010-10-26       Impact factor: 2.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.